Reply to the letter to the editor "Long-term cannabinoid receptor (CB1) blockade in obesity: Implications for the development of colorectal cancer"

International Journal of Cancer

Volumn 123, Issue 1, 2008, Pages 243-244

  Santoro, Antonietta ^a   Gazzerro, Patrizia ^a   Malfitano, Anna Maria ^a   Pisanti, Simona ^a   Laezza, Chiara ^b   Bifulco, Maurizio ^a  

^a UNIVERSITY OF SALERNO   (Italy)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID RECEPTOR; RIMONABANT;

CANCER GROWTH; CELL PROLIFERATION; CELL VIABILITY; COLORECTAL CANCER; INTESTINE MUCOSA; LETTER; OBESITY; PRIORITY JOURNAL; RECEPTOR BLOCKING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTI-OBESITY AGENTS; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL SURVIVAL; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICE; OBESITY; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; TIME FACTORS;

EID: 43949098595     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23507     Document Type: Letter

References (10)

1. Wright KL, Robertson DAF, Ward SG. Long term cannabinoid receptor (CB1) blockade in obesity: implication for the development of colorectal cancer. Int J Cancer 2008;122:1920-1.
2. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, Barth F, Calandra B, Pecceu F, Lupker J, Maffrand JP, Le Fur G, et al. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 1997;272:22330-9.
3. Navarro M, Carrera MR, Fratta W, Valverde O, Cossu G, Fattore L, Chowen JA, Gomez R, del Arco I, Villanua MA, Maldonado R, Koob GF, et al. Interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci 2001;15:5344-50.
4. Malfitano AM, Laezza C, Pisanti S, Gazzerro P, Bifulco M. Rimonabant (SR141716) exerts anti-proliferative and immunomodulatory effects in human peripheral blood mononuclear cells. Br J Pharmacol, in press.
5. Izzo AA, Aviello G, Petrosino S, Orlando P, Marsicano G, Lutz B, Borrelli F, Capasso R, Nigam S, Capasso F, Di Marzo V. Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. J Mol Med 2008;86:89-98.
6. Cheng L, Lai MD. Aberrant crypt foci as microscopic precursors of colorectal cancer. World J Gastroenterol 2003;9:2642-9.
7. Hawk ET, Umar A, Viner JL. Colorectal cancer chemoprevention - an overview of the science. Gastroenterology 2004;126:1423-47.
8. Ligresti A, Bisogno T, Matias I, De Petrocellis L, Cascio MG, Cosenza V, D'Argenio G, Scaglione G, Bifulco M, Sorrentini I, Di Marzo V. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 2003;125:677-87.
9. Notarnicola M, Messa C, Orlando A, Bifulco M, Laezza C, Gazzerro P, Caruso MG. Estrogenic induction of cannabinoid CB1 receptor in human colon cancer cell lines. Scand J Gastroenterol 2008;43:66-72.
10. Bifulco M, Grimaldi C, Gazzerro P, Pisanti S, Santoro A. Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects. Mol Pharmacol 2007;71:1445-556.